Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase

Éva Ruisanchez, Péter Dancs, Margit Kerék, Tamás Németh, Bernadett Faragó, Andrea Balogh, Renukadevi Patil, Brett L. Jennings, Károly Liliom, Kafait Malik, Alan V. Smrcka, Gabor Tigyi, Zoltán Benyó

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Lysophosphatidic acid (LPA) has been implicated as a mediator of several cardiovascular functions, but its potential involvement in the control of vascular tone is obscure. Here, we show that both LPA (18:1) and VPC31143 (a synthetic agonist of LPA1-3 receptors) relax intact mouse thoracic aorta with similar Emax values (53.9 and 51.9% of phenylephrine- induced precontraction), although the EC50 of LPA- and VPC31143-induced vasorelaxations were different (400 vs. 15 nM, respectively). Mechanical removal of the endothelium or genetic deletion of endothelial nitric oxide synthase (eNOS) not only diminished vasorelaxation by LPA or VPC31143 but converted it to vasoconstriction. Freshly isolated mouse aortic endothelial cells expressed LPA1, LPA2, LPA4 and LPA 5 transcripts. The LPA1,3 antagonist Ki16425, the LPA 1 antagonist AM095, and the genetic deletion of LPA1, but not that of LPA2, abolished LPA-induced vasorelaxation. Inhibition of the phosphoinositide 3 kinase-protein kinase B/Akt pathway by wortmannin or MK-2206 failed to influence the effect of LPA. However, pharmacological inhibition of phospholipase C (PLC) by U73122 or edelfosine, but not genetic deletion of PLCε, abolished LPA-induced vasorelaxation and indicated that a PLC enzyme, other than PLCε, mediates the response. In summary, the present study identifies LPA as an endothelium-dependent vasodilator substance acting via LPA1, PLC, and eNOS.

Original languageEnglish (US)
Pages (from-to)880-890
Number of pages11
JournalFASEB Journal
Volume28
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Lysophosphatidic Acid Receptors
Nitric Oxide Synthase Type III
Type C Phospholipases
Vasodilation
lysophosphatidic acid
Endothelium-Dependent Relaxing Factors
Proto-Oncogene Proteins c-akt
1-Phosphatidylinositol 4-Kinase
Endothelial cells
Phenylephrine
Phosphatidylinositols
Vasoconstriction
Thoracic Aorta
Endothelium
Blood Vessels
Endothelial Cells

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Ruisanchez, É., Dancs, P., Kerék, M., Németh, T., Faragó, B., Balogh, A., ... Benyó, Z. (2014). Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. FASEB Journal, 28(2), 880-890. https://doi.org/10.1096/fj.13-234997

Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. / Ruisanchez, Éva; Dancs, Péter; Kerék, Margit; Németh, Tamás; Faragó, Bernadett; Balogh, Andrea; Patil, Renukadevi; Jennings, Brett L.; Liliom, Károly; Malik, Kafait; Smrcka, Alan V.; Tigyi, Gabor; Benyó, Zoltán.

In: FASEB Journal, Vol. 28, No. 2, 01.01.2014, p. 880-890.

Research output: Contribution to journalArticle

Ruisanchez, É, Dancs, P, Kerék, M, Németh, T, Faragó, B, Balogh, A, Patil, R, Jennings, BL, Liliom, K, Malik, K, Smrcka, AV, Tigyi, G & Benyó, Z 2014, 'Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase', FASEB Journal, vol. 28, no. 2, pp. 880-890. https://doi.org/10.1096/fj.13-234997
Ruisanchez, Éva ; Dancs, Péter ; Kerék, Margit ; Németh, Tamás ; Faragó, Bernadett ; Balogh, Andrea ; Patil, Renukadevi ; Jennings, Brett L. ; Liliom, Károly ; Malik, Kafait ; Smrcka, Alan V. ; Tigyi, Gabor ; Benyó, Zoltán. / Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. In: FASEB Journal. 2014 ; Vol. 28, No. 2. pp. 880-890.
@article{914e033cabb24f339f36dd708c40012f,
title = "Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase",
abstract = "Lysophosphatidic acid (LPA) has been implicated as a mediator of several cardiovascular functions, but its potential involvement in the control of vascular tone is obscure. Here, we show that both LPA (18:1) and VPC31143 (a synthetic agonist of LPA1-3 receptors) relax intact mouse thoracic aorta with similar Emax values (53.9 and 51.9{\%} of phenylephrine- induced precontraction), although the EC50 of LPA- and VPC31143-induced vasorelaxations were different (400 vs. 15 nM, respectively). Mechanical removal of the endothelium or genetic deletion of endothelial nitric oxide synthase (eNOS) not only diminished vasorelaxation by LPA or VPC31143 but converted it to vasoconstriction. Freshly isolated mouse aortic endothelial cells expressed LPA1, LPA2, LPA4 and LPA 5 transcripts. The LPA1,3 antagonist Ki16425, the LPA 1 antagonist AM095, and the genetic deletion of LPA1, but not that of LPA2, abolished LPA-induced vasorelaxation. Inhibition of the phosphoinositide 3 kinase-protein kinase B/Akt pathway by wortmannin or MK-2206 failed to influence the effect of LPA. However, pharmacological inhibition of phospholipase C (PLC) by U73122 or edelfosine, but not genetic deletion of PLCε, abolished LPA-induced vasorelaxation and indicated that a PLC enzyme, other than PLCε, mediates the response. In summary, the present study identifies LPA as an endothelium-dependent vasodilator substance acting via LPA1, PLC, and eNOS.",
author = "{\'E}va Ruisanchez and P{\'e}ter Dancs and Margit Ker{\'e}k and Tam{\'a}s N{\'e}meth and Bernadett Farag{\'o} and Andrea Balogh and Renukadevi Patil and Jennings, {Brett L.} and K{\'a}roly Liliom and Kafait Malik and Smrcka, {Alan V.} and Gabor Tigyi and Zolt{\'a}n Beny{\'o}",
year = "2014",
month = "1",
day = "1",
doi = "10.1096/fj.13-234997",
language = "English (US)",
volume = "28",
pages = "880--890",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "2",

}

TY - JOUR

T1 - Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase

AU - Ruisanchez, Éva

AU - Dancs, Péter

AU - Kerék, Margit

AU - Németh, Tamás

AU - Faragó, Bernadett

AU - Balogh, Andrea

AU - Patil, Renukadevi

AU - Jennings, Brett L.

AU - Liliom, Károly

AU - Malik, Kafait

AU - Smrcka, Alan V.

AU - Tigyi, Gabor

AU - Benyó, Zoltán

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Lysophosphatidic acid (LPA) has been implicated as a mediator of several cardiovascular functions, but its potential involvement in the control of vascular tone is obscure. Here, we show that both LPA (18:1) and VPC31143 (a synthetic agonist of LPA1-3 receptors) relax intact mouse thoracic aorta with similar Emax values (53.9 and 51.9% of phenylephrine- induced precontraction), although the EC50 of LPA- and VPC31143-induced vasorelaxations were different (400 vs. 15 nM, respectively). Mechanical removal of the endothelium or genetic deletion of endothelial nitric oxide synthase (eNOS) not only diminished vasorelaxation by LPA or VPC31143 but converted it to vasoconstriction. Freshly isolated mouse aortic endothelial cells expressed LPA1, LPA2, LPA4 and LPA 5 transcripts. The LPA1,3 antagonist Ki16425, the LPA 1 antagonist AM095, and the genetic deletion of LPA1, but not that of LPA2, abolished LPA-induced vasorelaxation. Inhibition of the phosphoinositide 3 kinase-protein kinase B/Akt pathway by wortmannin or MK-2206 failed to influence the effect of LPA. However, pharmacological inhibition of phospholipase C (PLC) by U73122 or edelfosine, but not genetic deletion of PLCε, abolished LPA-induced vasorelaxation and indicated that a PLC enzyme, other than PLCε, mediates the response. In summary, the present study identifies LPA as an endothelium-dependent vasodilator substance acting via LPA1, PLC, and eNOS.

AB - Lysophosphatidic acid (LPA) has been implicated as a mediator of several cardiovascular functions, but its potential involvement in the control of vascular tone is obscure. Here, we show that both LPA (18:1) and VPC31143 (a synthetic agonist of LPA1-3 receptors) relax intact mouse thoracic aorta with similar Emax values (53.9 and 51.9% of phenylephrine- induced precontraction), although the EC50 of LPA- and VPC31143-induced vasorelaxations were different (400 vs. 15 nM, respectively). Mechanical removal of the endothelium or genetic deletion of endothelial nitric oxide synthase (eNOS) not only diminished vasorelaxation by LPA or VPC31143 but converted it to vasoconstriction. Freshly isolated mouse aortic endothelial cells expressed LPA1, LPA2, LPA4 and LPA 5 transcripts. The LPA1,3 antagonist Ki16425, the LPA 1 antagonist AM095, and the genetic deletion of LPA1, but not that of LPA2, abolished LPA-induced vasorelaxation. Inhibition of the phosphoinositide 3 kinase-protein kinase B/Akt pathway by wortmannin or MK-2206 failed to influence the effect of LPA. However, pharmacological inhibition of phospholipase C (PLC) by U73122 or edelfosine, but not genetic deletion of PLCε, abolished LPA-induced vasorelaxation and indicated that a PLC enzyme, other than PLCε, mediates the response. In summary, the present study identifies LPA as an endothelium-dependent vasodilator substance acting via LPA1, PLC, and eNOS.

UR - http://www.scopus.com/inward/record.url?scp=84897105499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897105499&partnerID=8YFLogxK

U2 - 10.1096/fj.13-234997

DO - 10.1096/fj.13-234997

M3 - Article

VL - 28

SP - 880

EP - 890

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 2

ER -